Targeting c-kit inhibits gefitinib resistant NSCLC cell growth and invasion through attenuations of stemness, EMT and acquired resistance

EGFR tyrosine kinase inhibitors (TKIs) are the first-line drugs for NSCLC. But, the acquired resistance limited their efficacy, so that the patients deteriorate eventually. Therefore, it is necessary to clarify the mechanism of the acquired resistance and overcome it for effective NSCLC therapy. In...

Full description

Saved in:
Bibliographic Details
Published in:Am J Cancer Res
Main Authors: Zhou, Yueling, Wang, Li, Sun, Zhen, Zhang, Jie, Wang, Xiujie
Format: Artigo
Language:Inglês
Published: e-Century Publishing Corporation 2020
Subjects:
Original Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7783754/
https://ncbi.nlm.nih.gov/pubmed/33414998
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items